<DOC>
	<DOCNO>NCT01925274</DOCNO>
	<brief_summary>This study investigate whether combination PF-05212384 plus Irinotecan improve progression free survival patient KRAS NRAS wild type metastatic colorectal cancer compare combination cetuximab plus Irinotecan . A Japanese Lead Cohort assess safety combination PF-05212384 + irinotecan patient enrol Japanese site .</brief_summary>
	<brief_title>A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>KRAS NRAS wild type metastatic colorectal cancer Progression follow treatment colorectal cancer irinotecan , oxaliplatin fluoropyrimidine therapy metastatic setting . Eastern Cooperative Oncology Group [ ECOG ] Performance Status 0 , 1 , 2 At least one measurable lesion Response Evaluation Criterion Solid Tumors [ RECIST ] More 2 prior cytotoxic chemotherapy regimens metastatic colorectal cancer . Prior treatment PI3K , mTOR , AKT EGFR inhibitor Patients discontinue treatment prior irinotecan therapy due toxicity . Prior radiation pelvis abdomen Patients history interstitial lung disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>metastatic colorectal cancer</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>KRAS</keyword>
	<keyword>colon cancer</keyword>
	<keyword>mCRC</keyword>
	<keyword>CRC</keyword>
	<keyword>PF-05212384</keyword>
	<keyword>KRAS wild type colorectal cancer</keyword>
	<keyword>irinotecan</keyword>
	<keyword>cetuximab</keyword>
	<keyword>NRAS</keyword>
</DOC>